Valeant Establishes Drug Pricing Committee

Valeant Pharmaceuticals International has established a drug pricing committee, a move that comes a week after company representatives pledged to review its pricing model in the face of withering congressional criticism.

The company’s newly formed Patient Access and Pricing Committee will be led by incoming CEO Joseph Papa and will include doctors, scientists, employees and executives, Valeant officials said.

“Valeant has made mistakes in how it prices its drugs in the past, and we are committed to ensuring those mistakes are not repeated,” Papa acknowledged.